Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda
Dr. Jänne, Director, Lowe Center for Thoracic Oncology, Director, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine, Harvard Medical School, shares how he would treat 2nd line patients who previously received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy
source: https://medinaportal.net
Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/
Categories: